We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current PLX market cap is 129.6M. The company's latest EPS is USD 0.1129 and P/E is 15.50.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10.35M | 10.49M | 3.75M | 13.47M | 17.96M |
| Operating Income | -1.89M | -5.62M | -4.86M | -2.43M | 3.99M |
| Net Income | -1.85M | -6.04M | -4.6M | -2.2M | 3.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 54.69M | 62.9M | 38.35M | 47.64M | 65.49M |
| Operating Income | -10.72M | 2.71M | -20.46M | -13.01M | 10.46M |
| Net Income | -18.28M | -6.52M | -27.58M | -14.93M | 8.31M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 87.57M | 84.43M | 89.83M | 91.54M | 61.56M |
| Total Liabilities | 49.32M | 50.87M | 60.04M | 62.96M | 29.13M |
| Total Equity | 38.25M | 33.57M | 29.79M | 28.58M | 32.44M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 45.39M | 67.93M | 73.67M | 55.79M | 84.43M |
| Total Liabilities | 115.71M | 94.97M | 79.7M | 66.43M | 50.87M |
| Total Equity | -70.32M | -27.04M | -6.04M | -10.64M | 33.57M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -4.91M | -1.32M | 4.19M | 578k | 4.68M |
| Investing | -16.37M | -16.71M | -606k | -786k | 19.54M |
| Financing | 24.67M | 24.67M | N/A | N/A | -20.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -19.36M | -26.11M | -10.29M | -25M | -1.32M |
| Investing | -883k | -19.95M | 18.92M | -5.04M | -16.71M |
| Financing | N/A | 46.47M | 12.08M | 8.24M | 24.67M |
| Market Cap | 129.6M |
| Price to Earnings Ratio | 15.50 |
| Price to Sales Ratio | 1.97 |
| Price to Cash Ratio | 5.45 |
| Price to Book Ratio | 3.84 |
| Dividend Yield | - |
| Shares Outstanding | 73.63M |
| Average Volume (1 week) | 393.58k |
| Average Volume (1 Month) | 394.59k |
| 52 Week Change | 8.64% |
| 52 Week High | 1.90 |
| 52 Week Low | 0.8214 |
| Spread (Intraday) | 0.04 (2.27%) |
| Company Name | Protalix BioTherapeutics Inc |
| Address |
108 w. 13th street wilmington, delaware 19801 |
| Website | https://protalix.com |
| Industry | management services (8741) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
